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Abstract
Background: Klebsiella pneumonia carbapenemases (KPCs) are able to hydrolyze the carbapenems, which cause
many bacteria resistance to multiple classes of antibiotics, so the rapid dissemination of KPCs is worrisome.
Laboratory identification of KPCs-harboring clinical isolates would be a key to limit the spread of the bacteria. This
study would evaluate a rapid low-cost real-time PCR assay to detect KPCs.
Methods: Real-time PCR assay based on SYBR GreenIwas designed to amplify a 106 bp product of the blaKPC gene
from the159 clinical Gram-negative isolates resistant to several classes of β-lactam antibiotics through antimicrobial
susceptibility testing. We confirmed the results of real-time PCR assay by the conventional PCR-sequencing. At the
same time, KPCs of these clinical isolates were detected by the modified Hodge test (MHT). Then we compared the
results of real-time PCR assay with those of MHT from the sensitivity and specificity. Moreover, we evaluated the
sensitivity of the real-time PCR assay.
Results: The sensitivity and specificity of the results of the real-time PCR assay compared with those of MHT was
29/29(100 %) and 130/130(100 %), respectively. The results of the real-time PCR and the MHT were strongly
consistent (Exact Sig. (2-tailed) =1. 000; McNemar test). The real-time PCR detection limit was about 0.8 cfu using
clinical isolates.
Conclusion: The real-time PCR assay could rapidly and accurately detect KPCs -harboring strains with high analytical
sensitivity and specificity.
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Background
Carbapenems are widely used to treat serious infections
caused by multi-resistant Gram-negative bacteria. How-
ever, beginning with the initial description of a novel
KPC from an isolate of K. pneumoniae in 2001 [1], car-
bapenem resistance in Enterobacteriaceae has been rap-
idly increasing. KPCs are able to hydrolyze the
carbapenems, and cause resistance to multiple classes of
antibiotics. Treatment of KPC-producing bacterial infec-
tion is thus a considerable challenge for clinicians. KPCs
have been reported worldwide, such as North America,
South America, Greece, Israel, Puerto Rico, China and so
on [2-6]. The expanding geographic spread of KPCs
underscores the importance of clinical recognition of
these enzymes. In addition, KPCs have been found in
bacteria other than K. pneumoniae, including K. oxytoca
[7,8], P. mirabilis [9], Acinetobacter spp [6], P. aerugi-
nosa , C. freundii [10], S. marcescens and E. coli [11].
This rapid dissemination of KPC is worrisome. Labora-
tory identification of KPC-harboring clinical isolates will
be critical for limiting the spread.
However, detection of KPC -harboring stains in the
clinical laboratory remained a difficult task. The failure
of automated susceptibility testing systems to detect
KPC-mediated carbapenems resistance was previously
reported [12-14]. In 2009, the Clinical Laboratory Stan-
dards Institute (CLSI) guidelines (M100) recommended
MHT to detect carbapenemase production. Wang et al.
[15] noted that false positive results could occur when
the MHT was used to detect carbapenemase in ESBL-
producing isolates. MHT is time-consuming and not
routinely tested for E. cloacae, P. aeruginosa in labora-
tory, so that many molecular detection of blaKPC genes
were evaluated [16-19]. Rapid and sensitive blaKPC assays
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bacteria in hospitalized patients.
In this paper, we would describe the development of a
low-cost real-time PCR assay to screen clinical isolates for
blaKPC.
Materials and methods
Bacterial strains
The following reference bacterial strains were the negative
controls of blaKPC: K. pneumoniaeATCC13883, extended-
spectrum-b-lactamase-positive K. pneumoniaeATCC
700603,A .b a u m a n i i ATCC 19606, P. aeruginasaATCC
27853, C. albicansATCC 90029, E. coliATCC25922, E.
faeciumATCC 35667 and methicillin-resistant S. aureu-
sATCC 43300.
The 159 clinical isolates including K. pneumoniae, E.
coli, E. cloacae, K. oxytoca, S. marcescens, P. mirabilis,
MDR A.baumanii and MDR P. aeruginasa. were recov-
ered from multiple infection sites like blood, wound,
sputum, catheter, urine and pleural effusion from Beijing
Tongren Hospital. These clinical isolates were resistant
to several classes of β-lactam antibiotics, which were
identified by antimicrobial susceptibility testing.
Antimicrobial susceptibility testing
Antimicrobial susceptibility testing was performed with
the Vitek 2 susceptibility card AST-GN13 by Vitek 2
automated system (BioMérieux Inc, Durham, NC)
according to the manufacturer’s instructions. Minimum
inhibitory concentration (MIC) results of imipenem and
ertapenem were classified as susceptible, intermediate, or
resistant based on the 2010 CLSI breakpoints (suscep-
tible, ≤ 1 μg/ml and≤0.25 μg/ml; intermediate, 2 μg/ml
and 0.5 μg/ml; resistant, ≥ 4 μg/ml and≥1 μg/ml,
respectively). However, the AST-GN13 card cannot clas-
sify organisms as susceptible to ertapenem without the
dilutions less than 0.5 μg/ml. All clinical isolates were
subsequently tested by MHT. The indicator strains in
MHT were E. coli ATCC 25922 for Enterobacteriaceae
and K.pneumoniae ATCC 700603 for non- Enterobacter-
iaceae like P.aeruginosa [20].
DNA isolation
Bacterial strains were grown on MacConkey agar and
incubated overnight at 35°C. One colony was resuspended
in 100 μl of sterile distilled water and the cells were lysed
by heating at 100°C for 10 min. Cellular debris was
removed by centrifugation at 13000 g for 10 min, and the
supernatant was used as a source of template DNA for
amplification.
For analytical sensitivity based on bacterial colony-
forming unit (cfu), DNA isolation was performed using the
DNeasy Blood&Tissue Kit (Qiagen Sciences, Maryland,
USA) according to the protocol suggested by the
manufacture. In brief, a bacterial suspension equivalent to
that of a 2.0 McFarland standard was prepared in saline,
then 200 μl( 8 . 0×1 0
7 cfu ) suspension were serially diluted
10-fold in saline. Bacterial total nucleic acid was extracted
from 200 μl of each dilution and then eluted in 50 μle l u -
tion buffer and stored at −20°C.
blaKPC detection by PCR –sequencing
The presence of blaKPC was confirmed by conventional
PCR and sequencing [1]. The primers included the
forward (5’-TGTCACTGTATCGCCGTC-3’) and the
reverse (5’- CTCAGTGCTCTACAGAAAACC-3’) , The
PCR reaction system contained 0.5 μM each primer,
2×EasyTaq PCR SuperMix (TransGen Biotech, Beijing,
China) and 2 μl DNA template. The reactions were amp-
lified in a My Cycler thermal cycler (BIO-RAD, USA).
Cycling parameters were 5 min at 95°C, followed by 35
cycles of 1 min at 95°C, 30s at 58°C, and 1 min 30 s at
72°C. The PCR amplification was ended by a final extension
at 72°C for 10 min. sequencing of the PCR products was
commercially performed by SinoGenoMax Co. Ltd (Beijing,
China). For sequence analysis, the BLAST program from
the National Center for Biotechnology Information Web
s i t ew a su s e d( h t t p :/ / w w w .n c b i .n l m .n i h . g o v / B L A S T ) .
blaKPC detection by real-time PCR
The forward primer sequence (5’-TTGTTGATTGGC
TAAAGGG-3’) and reverse primer sequence (5’- CCATA-
CACTCCGCAGGTT-3’) were designed in the conservative
region of several blaKPC types (blaKPC −2 to blaKPC-13). The
blaKPC amplicon was 106 base pairs (GenBank: EU244644).
The 25 μl real-time PCR mixture contained 12. 5 μl
TransStart Green qPCR super MIX (TransGen Biotech,
Beijing, China), 0.5 μl PCR enhancer (TransGen Biotech,
Beijing, China), 0.2 μMe a c hp r i m e r ,9μl sterile distilled
water and 2 μl DNA template. Real-time PCR amplifica-
tion was performed using the Roche Light cycler 480 Real-
time system (Roche Diagnostics, Mannheim, Germany).
Cycling parameters were 5 min at 95°C, followed by 40
cycles of 15 s at 95°C, 15 s at 55°C, and 30 s at 72°C. Single
fluorescence detection was performed in each cycle at 55°
C. Melting curve acquisitions were done immediately after
the final amplification step by heating at 96°C for 5 s, cool-
ing to 55°C for 1 min, and heating slowly at 0.11°C per sec-
ond to 96°C with continuous fluorescence recording.
Melting curves were recorded by plotting fluorescence sig-
nal intensity versus temperature. Amplicon melting tem-
peratures(Tm) were determined by calculating the
derivative of the curve using Roche Light cycler 480 soft-
ware. The results were visualized by plotting the negative
derivative against temperature.
Specificity and sensitivity
In order to determine analytical sensitivity of our assay,
blaKPC real-time PCR experiments were performed on 10-
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7 cfu). To
evaluate the analytical specificity, a panel of reference
stains and clinical strains resistant to several classes of β-
lactam antibiotics was tested. For statistical analysis, we
used the MHT as the reference standard. The differences
between sensitivities of the real-time PCR assay and MHT
were evaluated with the McNemar test.
Results
The specificities of the real-time PCR primers for the de-
tection of blaKPC genes were evaluated by the BLAST
search program, available at www.ncbi.nlm.nih.gov.
The blaKPC r e a l - t i m eP C Ra s s a yw a sn e g a t i v ew i t h
DNA extracted from the following reference bacterial
isolates: K.pneumoniae ATCC 13883, extended-spectrum-
b-lactamase-positive K.pneumoniae ATCC 700603,A .
baumanii ATCC 19606, P. aeruginasa ATCC 27853, C.
albicans ATCC 90029, E. coli. ATCC25922, E. faeciu-
mATCC 35667 and methicillin-resistant S. aureusATCC
43300.
159 clinical isolates were categorized according to the
susceptibility of imipenem or ertapenem (Table 1). 53 iso-
lates were intermediate to resistant to imipenem or ertape-
nem, and 106 isolates were susceptible to carbapenems. 29
clinical isolates with carbapenem resistance or decreased
susceptibility were positive by MHT and by real-time PCR
and sequencing, respectively. The 29 clinical isolates
included 20K. pneumoniae (MICs: imipenem≥16 μg/ml,
ertapenem≥8 μg/ml), 3 E. coli (one strain MICs: imipe-
nem≤1 μg/ml, ertapenem=2 μg/ml; two strains MICs:
imipenem≥16 μg/ml, ertapenem≥8 μg/ml), 4 E. cloacae
(MICs: imipenem≥16 μg/ml, ertapenem≥8 μg/ml), one S.
marcescens (MICs: imipenem≥16 μg/ml, ertapenem≥8
μg/ml), and one MDR A. baumanii (MICs: imipenem≥16
μg/ml, ertapenem≥8 μg/ml). One carbapenem-resistant
isolate of K. pneumoniae (MICs: imipenem≥16 μg/ml,
ertapenem≥8 μg/ml) recovered from sputum was MHT
( − )/blaKPC ( − ) in our assay. In addition, both isolate
of K. pneumonia (MICs: imipenem≤1 μg/ml, ertape-
nem≥8 μg/ml) and E. coli (MICs: imipenem≤1 μg/ml,
ertapenem=2 μg/ml) were MHT ( − )/blaKPC ( − ),
which were recovered from catheter. All 130 isolates
(33K. pneumoniae,4 2E. coli,1 5E. cloacae,1 0 K. oxy-
toca,o n eS. marcescens,8P. mirabilis,1 0M D RA. bau-
manii and 11 MDR P. aeruginasa )w e r eM H T(− )/
blaKPC ( − ) (Table 2). The sensitivity of the real-time
PCR assay as compared to the MHT was 29/29(100 %)
with a specificity of 130/130 (100 %). The results of the
real-time PCR and the MHT were strongly consistent
(Exact Sig. (2-tailed) =1.000; McNemar test).
All blaKPC genes of KPC-producing isolates in this
study were verified as blaKPC-2 by sequencing assay.
The blaKPC amplicon was distinguished by its specific
Tm value. Under our experimental conditions, analysis
of the melting curve profile of the PCR products indi-
cated that the products peaked at about 89°C (Figure 1).
The analytical sensitivity of the blaKPC real-time PCR
assay was determined after serially diluting known concen-
trations (8.0×10
7 cfu) of clinical isolated carbapenems-
resisant K. pneumoniae. The dynamic range of the assay
covered nine orders of magnitude from 8.0×10
7 to 0.8 cfu.
blaKPC specific fluorescent peaks were detected in the iso-
lates dilutions to about 0.8 cfu (Figure 2).
Discussion
Along with the wide use of carbapenem antibiotics,
KPCs appeared a major public health concern. Bacterial
isolates producing KPCs are able to hydrolyze a broad
spectrum of β-lactams including the penicillins, cepha-
losporins, carbapenems and monobactam. They have the
potential to spread rapidly in hospital environments to
cause nosocomial infections with high mortality rates
[21]. KPC-producing Enterobacteriaceae stains are
increasingly spreading throughout China [2,9,11,22]. The
dominant clone of KPC-producing K. pneumoniae in
China is ST11, which is closely related to ST258 reported
worldwide [23]. A rapid method confirming KPCs is
significant to control this spread.
In 2009, the CLSI recommended MHT to screen for
the production of carbapenemase in Enterobacteriaceae
Table 1 Results of Carbapenem susceptibility and MHT of
clinical isolates
Species No. of
isolates
No. of Carbapenem
susceptibility
No. of MHT*
Intermediate
to resistant
Susceptible Positive Negative
K. pneumoniae 53 22 31 20 33
E. coli 45 4 41 3 42
E. cloacae 19 4 15 4 15
K. oxytoca 10 0 10 0 10
P. mirabilis 80 8 0 8
S. marcescens 21 1 1 1
MDR A.
baumanii
11 11 0 1 10
MDR P.
aeruginasa
11 11 0 0 11
*: MHT modified Hodge test.
Table 2 blaKPC Real-time-PCR results compared with the
MHT.
blaKPC Real-
time-PCR*
MHT
Positive Negative
Positive 29 0
Negative 0 130
*: The percent sensitivity was 100 %, and the percent specificity was 100 %.
Exact Sig. (2-tailed) =1.000; McNemar test.
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inhibition zones measured by disc diffusion. In 2010,
Carbapenem breakpoints have changed in M100-S20U
and M100-S21 with 2-fold lower MICs of each category
(susceptible, intermediate, and resistant) for the Entero-
bacteriaceae for imipenem, meropenem, and ertapenem.
According to the new criteria, the initial screen test and
the confirmatory test by MHT are no longer necessary
for routine patient testing. However, one isolate of E. coli
with MIC to imipenem as low as 1 μg/ml was confirmed
a sM H T(+)/blaKPC ( + ) in our study. Decreased erta-
penem susceptibility has been considered as one of the
most sensitive phenotypic indicators of KPC production,
but it has been found to be nonspecific [24,25]. In our la-
boratory, two clinical isolates MICs to ertapenem as high
as 2 μg/ml to 8 μg/ml were MHT ( − )/blaKPC ( − ).
Despite CLSI new recommendations, our laboratory con-
tinued to confirm KPC using MHT or PCR.
The sensitivity and specificity of the MHT have been
shown to exceed 90 %; however, several reports have
noted false positive results occurred when the MHT was
used to detect carbapenemase in ESBL-producing
isolates [15,26]. In addition, it may not be the ideal
phenotypic confirmatory test for KPCs since interpret-
ation can be difficult for some isolates such as A. bau-
manii, P. aeruginasa. In our study, we adjusted the
Figure 1 Plot of the negative derivative of the melting curves vs. temperature: peak indicates the Tm (about 89°C) of isolates. NTC: no
template control.
Figure 2 Analytical sensitivity of the blaKPC real-time-PCR assay showing a minimum detection limit of 0.8 CFU.
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Enterobacteriaceae in order to eliminate the incidence of
indeterminate results of MHT [20]. Thus, an alternative
method may prove to be more useful. During the recent
few years, molecular methods have been used to rapidly
detect blaKPC genes. In particular, real-time PCR assays
offered the advantage of shorter turnaround time, which
were even developed to detect KPC-containing strains
with high analytical specificity and sensitivity in surveil-
lance specimens [27,28].
In this study, we validated a rapid, sensitive, and specific
real-time-PCR assay for the detection of blaKPC genes.
This assay can be performed in less than 4 hours, which
will reduce the chance of spreading the organism in the
hospital. The real-time PCR assay specifity and sensitivity
were 100 % compared to phenotypic KPC activity assessed
by MHTand sequencing. Thirteen KPC gene variants have
been described, classified in sequential numeric order from
blaKPC-1/2 to blaKPC-13.T h eblaKPC genes are characterized
by nonsynonymous single nucleotide substitutions [17].
Our sequencing results showed all 29 KPC-producing iso-
lates harbored blaKPC-2 gene. KPC-2 clinical isolates were
widely isolated in most parts of China [23,29]. Last year, Li
et al [30] in China firstly described KPC-3-harboring E.
coli and C. freundii. Although KPC-2 and KPC-3 were well
described throughout China, we designed the primers in
conservative areas to ensure that our assay could almost
detect the variants currently described. We identified
blaKPC genes by melting curve analysis of the amplification
product using SYBR GreenIwith many advantages like
low-cost and easy to use. The Tm value of the blaKPC gene
was detected at about 89°C. Our assay sensitivity is about
one cfu sufficient to detect blaKPC–containing isolates.
Conclusions
The real-time PCR assay described here provides a useful
screening test to detect blaKPC genes rapidly and accur-
ately. Although the real-time PCR assay was unable to
identify the specific gene in the blaKPC family in clinical
isolates, accurate and rapid identification of this kind of
resistance genes is the first step to control their spread.
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